All GLG News Analyses Filed Under: Healthcare Services
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
-
Adam FeinFounder & PresidentPEMBROKE CONSULTING INC
A Faulty Track-and-Trace Cost Model for Pharmacies
July 2, 2008
A new report from Accenture attempts to assess the financial costs of implementing a serialized track-and-trace system for the U.S. pharmacy supply chain. But even if we assume that Accenture did a credible and impartial job building their pharmacy cost models, the estimates in this report reflect an extreme situation that no one is seriously advocating. In other words, Accenture’s calculations may not be technically wrong, but its conclusions are highly misleading given actual proposals and practices regarding supply chain security. Thus, you should think of this report as the inflated, upper bound, "worst case" costs of a track-and-trace thought experiment.
-
Shawn BurgessVice President & Chief Information OfficerAbrazo Health System
The economy's impact in Healthcare
June 24, 2008
Health Care in a Lousy Economy | www.hhnmag.com
Typically the macro economy does not have immediate effect to the healthcare market. As the current US economy struggles from the rising cost of fuel and burst of the housing and mortgage bubble the effect is beginning to be realized in various areas that impact the healthcare market.
-
Jeff is in accounting not a healthcare provider.
June 23, 2008
Health Care in a Lousy Economy | www.hhnmag.com
Jeff is very savy about the probems in healthcare except for the fact that there may not be time 6 to 18 months later where we may se a rebound. Its already been 18 months since fuel costs have skyrocketed and the providers that are service oriented are not going to recover due to the inability to pass on the cost of delivery to the end user. No one provider can continue to serve in an environment where cuts in reimbursements have been severe since 2006. Some providers in home care have averaged a 56% cut and then add on the fuel increase. No the real world does not look for a rebound in Mr Lutz time period. There must be a fix very soon or the amout of providers will dwindle and costs will again skyrocket. Time to look at placing money in a Health Savings account or a strong tin can because you are going to need it in the future to pay for your healthcare.
-
Adam SchaffnerAssistant Professor of Clinical Plastic SurgeryGeorgetown University Medical Center - CC
Controlled Substances: Can be a Hot Commodity in the Wrong Hands
June 18, 2008
An Open Letter to Our Customers | www.cardinal.com
Controlled substances are invaluable in the attempt to control pain for many patients. Unfortunately, some criminals attempt to obtain these substances for personal gain as they are a valuable commodity on the black market. Therefore, it is of the utmost importance that industry and the DEA work closely together to strengthen and protect the integrity of the supply chain. Strengthening all links of the supply chain may result in a stronger economy which benefits all Americans.
-
Adam FeinFounder & PresidentPEMBROKE CONSULTING INC
New Twists for the AWP/First Databank Settlement
June 17, 2008
Drug database firm to pay $1 million to settle price-fixing suit | www.mercurynews.com
Average Wholesale Price (AWP) data for pharmaceuticals is still being published, but will continue to lose appeal as a reimbursement benchmark for pharmacies and Pharmacy benefit managers (PBMs). The latest amended (and still unapproved) settlement does not require First Databank to stop publishing AWP or roll back AWP on all drugs. Nonetheless, First Databank has announced that it will unilaterally roll back the AWP for all drugs to 1.20 and discontinue publishing the Blue Book AWP data independent of the litigation. So the outcome would be the same (no more published AWP) although the currently proposed settlement does not technically require the demise of AWP.
-
Genetic testing initially will promote Chaos and misinformation
June 16, 2008
Experts see boost to genetic testing from US bill | www.reuters.com
As a clinician leader for some time, it is overtly obvious that comprehensive genetic testing will be fraught with misinterpretation and will lead to consumer confusion and potentially wrong life behavior. Genetic testing has been available for 2-3 decades on a very limited basis and for specific fetal diseases yet physicians wholly inadequately trained are referring patients to nursing geneticists with a 85% incorrect diagnosis or treatment recommendations for patients. This wholesale look into the future will bring chaos and fright to many patients.
-
Adam FeinFounder & PresidentPEMBROKE CONSULTING INC
Cardinal Health Apologizes To Customers
June 6, 2008
An Open Letter to Our Customers | www.cardinal.com
Cardinal Health (CAH) has recently started publicizing An Open Letter to Our Customers from Chairman and CEO Kerry Clark. Cardinal is still struggling to balance their enforcement responsibilities with the legitimate needs of pharmacies and patients. While Cardinal desperately needs to resolve its DEA issues, I think that the company still has an opportunity to recover from its missteps and regain some lost market share.
-
June 4, 2008
Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA | www.pipelinereview.com
Mylan is positioned for growth in developing markets They have developed a presence in markets that they will need to have access to to compete with the Teva's and Sandoz's of the world Outlet for the older products that Mylan offers as the develop newer products for the more established market places. Potential access to low cost drugs as well
-
Adam FeinFounder & PresidentPEMBROKE CONSULTING INC
More Trouble for Cardinal Health
June 2, 2008
State investigating Cardinal | dispatch.com
A fifth Cardinal Health (CAH) location is now under investigation for allegedly failing to report “suspicious orders” of controlled substances from its Findlay, OH, warehouse. Cardinal Health has requested a hearing before the pharmacy board, so I presume nothing will happen until then. Penalties could range from a fine (most likely, IMHO) to revocation of its wholesale license (improbable but possible).
-
New Drug Discovery Pact with GVK BIO allows Wyeth to increase its Biotechnical Capacity.
May 30, 2008
GVK BIO enters into Drug Discovery Pact with Wyeth Pharmaceuticals | www.pipelinereview.com
Biotechnological Products have been emerging rapidly in the US/global drug market ever since the emergence of Genetech (ticker:DNA) and its break out drugs Rituxan (rituximab) and TNKase (tenecteplase). Since then, both brandname (ie Pfizer and Merck) as well as large generic pharmaceutical companies have been looking to strategically ally themselves with talented, emerging biotechnological companies. For more information on emerging biotechnological companies please refer to http://stockmd.wordpress.com/.
- Subscribe to Updates
-
Leading institutions connect with members of the Healthcare councils through GLG
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Most Popular Healthcare Services News
-
Ghana Targets Health Tourism Boom: More Evidence of Globalization
October 31, 2009
-
Express Scripts feeling Growing Pains
October 29, 2009
-
Panvax H1N1 approval good for Swine Flu Pandemic Control
September 21, 2009
-
ANATOMICAL PATHOLOGY BUSINESS ANALYSIS
September 4, 2009
-
Why is Healthcare Reform Losing Popularity
August 28, 2009